Mechanism of action and therapeutic potential of novel adamantyl retinoid-related molecules

Current Cancer Therapy Reviews

Volumn 2, Issue 2, 2006, Pages 185-198

  Piedrafita, F Javier ^a   Ortiz, Maria A ^a  

^a SIDNEY KIMMEL CANCER CENTER   (United States)

Author keywords

Adamantyl retinoid related molecules; Apoptosis; Atypical retinoids; I B kinase inhibitor; Nuclear retinoid receptors; Stress kinases

Indexed keywords

3 [3' (1 ADAMANTYL) 4' HYDROXYBIPHENYL 4 YL]ACRYLIC ACID; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 NITROPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 6 [3 (1 ADAMANTYL) 4 HYDROXYPHENYL] 2 NAPHTHOIC ACID; ACETYLCYSTEINE; ADAMANTANE DERIVATIVE; ADAPALENE; AGN 193198; ALITRETINOIN; ANTINEOPLASTIC AGENT; BEXAROTENE; CD 2325; FENRETINIDE; GEFITINIB; HETEROAROTINOID DERIVATIVE; I KAPPA B KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; MX 2870 1; MX 3350 1; MX 781; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOID DERIVATIVE; RETINOID X RECEPTOR; RETINOL DERIVATIVE; SHETA 2; STI 1926; STRESS ACTIVATED PROTEIN KINASE; TAMOXIFEN; TAZAROTENE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER DIAGNOSIS; CANCER INHIBITION; CANCER MORTALITY; CANCER PREVENTION; CANCER RESEARCH; CARCINOGENESIS; CELL DIFFERENTIATION; CELL GROWTH; CLINICAL TRIAL; CYTOSOL; DRUG RESPONSE; EARLY DIAGNOSIS; ENZYME ACTIVATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MITOCHONDRION; NONHUMAN; PREDICTION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SKIN DISEASE; SKIN LYMPHOMA; STRESS; UNITED STATES; UNSPECIFIED SIDE EFFECT;

EID: 33746126909     PISSN: 15733947     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339406776872852     Document Type: Review

References (145)

1. Piedrafita FJ, Pfahl M. In: Nau H, Blaner WS Eds, Retinoids: the biochemical and molecular basis of vitamin A and retinoid action. Berlin, Springer-Verlag 1999; 153-84.
2. Orfanos CE, Zouboulis CC, Almond-Roesler B, Geilen CC. Current use and future potential role of retinoids in dermatology. Drugs 1997; 53: 358-88.
3. Degos L, Wang ZY. All trans retinoic acid in acute promyelocytic leukemia. Oncogene 2001; 20: 7140-5.
4. Jimenez-Lara AM, Clarke N, Altucci L, Gronemeyer H. Retinoic-acid-induced apoptosis in leukemia cells. Trends Mol Med 2004; 10: 508-15.
5. Ortiz MA, Bayon Y, Lopez-Hernandez FJ, Piedrafita FJ. Retinoids in combination therapies for the treatment of cancer: mechanisms and perspectives. Drug Resist Updat 2002; 5: 162-75.
6. Lu XP, Fanjul AN, Picard N, et al. Novel retinoid-related molecules as apoptosis inducers and effective inhibitors of human lung cancer cells in vivo. Nat Med 1997; 3: 686-90.
7. Fanjul AN, Piedrafita FJ, Al-Shamma H, Pfahl M. Apoptosis induction and potent antiestrogen receptor-negative breast cancer activity in vivo by a retinoid antagonist. Cancer Res 1998; 58: 4607-10.
8. Benbrook DM, Kamelle SA, Guruswamy SB, et al. Flexible heteroarotinoids (Flex-Hets) exhibit improved therapeutic ratios as anti-cancer agents over retinoic acid receptor agonists. Invest New Drugs 2005; 23: 417-28.
9. Shao Z-M, Dawson MI, Li XS, et al. p53 independent G0/G1 arrest and apoptosis induced by a novel retinoid in human breast cancer cells. Oncogene 1995; 11: 493-504.
10. Piedrafita FJ, Pfahl M. Retinoid-induced apoptosis and Sp 1 cleavage occur independently of transcription and require caspase activation. Mol Cell Biol 1997; 17: 6348-58.
11. Suzui M, Masuda M, Lim JT, Albanese C, Pestell RG, Weinstein IB. Growth inhibition of human hepatoma cells by acyclic retinoid is associated with induction of p21(CIP1) and inhibition of expression of cyclin D1. Cancer Res 2002; 62: 3997-4006.
12. Chen Y, Buck J, Derguini F. Anhydroretinol induces oxidative stress and cell death. Cancer Res 1999; 59: 3985-90.
13. Delia D, Aiello A, Lombardi L, et al. N-(4-hydroxyphenyl) retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res 1993; 53: 6036-41.
14. Delia D, Aiello A, Meroni L, Nicolini M, Reed JC, Pierotti MA. Role of antioxidants and intracellular free radicals in retinamide-induced cell death. Carcinogenesis 1997; 18: 943-8.
15. Liu S, Brown CW, Berlin KD, et al. Synthesis of flexible sulfur-containing heteroarotinoids that induce apoptosis and reactive oxygen species with discrimination between malignant and benign cells. J Med Chem 2004; 47: 999-1007.
16. Chun KH, Benbrook DM, Berlin KD, Hong WK, Lotan R. The synthetic heteroarotinoid SHetA2 induces apoptosis in squamous carcinoma cells through a receptor-independent and mitochondria-dependent pathway. Cancer Res 2003; 63: 3826-32.
17. Gronemeyer H, Gustafsson JA, Laudet V. Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 2004; 3: 950-64.
18. Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell 1995; 83: 841-50.
19. McKenna NJ, O'Malley BW. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 2002; 108: 465-74.
20. Lonard DM, O'Malley BW. Expanding functional diversity of the coactivators. Trends Biochem Sci 2005; 30: 126-32.
21. Chen H, Lin RJ, Xie W, Wilpitz D, Evans RM. Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase. Cell 1999; 98: 675-86.
22. Gu W, Malik S, Ito M, et al. A novel human SRB/MED-containing cofactor complex, SMCC, involved in transcription regulation. Mol Cell 1999; 3: 97-108.
23. Fondell JD, Ge H, Roeder RG. Ligand induction of a transcriptionally active thyroid hormone receptor coactivator complex. Proc Natl Acad Sci USA 1996; 93: 8329-33.
24. Rachez C, Suldan Z, Ward J, et al. A novel protein complex that interacts with the vitamin D3 receptor in a ligand-dependent manner and enhances VDR transactivation in a cell-free system. Genes Dev 1998; 12: 1787-800.
25. Germain P, Altucci L, Bourguet W, Rochette-Egly C, Gronemeyer H. Nuclear receptor superfamily: principles of signaling. Pure Appl Chem 2003; 75: 1619-64.
26. Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ. Nuclear receptors and lipid physiology: opening the X-files. Science 2001; 294: 1866-70.
27. Crettaz M, Baron A, Siegenthaler G, Hunziker W. Ligand specificities of recombinant retinoic acid receptors RARα and RARβ. Biochem J 1990; 272: 391-7.
28. Lehmann JM, Dawson MI, Hobbs PD, Husmann M, Pfahl M. Identification of retinoids with Nuclear Receptor subtype-selective activities. Cancer Res 1991; 51: 4804-9.
29. Graupner G, Malle G, maignan J, Lang G, Prunieras M, Pfahl M. 6′-substituted naphthalene-2-carboxylic acid analogs, a new class of retinoic acid receptor subtype-specific ligands. Biochem Biophys Res Commun 1991; 179: 1554-61.
30. Beard RL, Chandraratna RAS. In: Nau H, Blaner WS Eds, Retinoids: the biochemical and molecular basis of vitamin A and retinoid action. Berlin, Springer 1999; 185-213.
31. Kagechika H, Shudo K. Synthetic retinoids: recent developments concerning structure and clinical utility. J Med Chem 2005; 48: 5875-83.
32. Jong L, Lehmann JM, Hobbs PD, et al. Conformational effects on retinoid receptor selectivity. 1. Effect of 9-double bond geometry on retinoid X receptor activity. J Med Chem 1993; 36: 2605-13.
33. Beard RL, Gil DW, Marler DK, et al. Structural basis for the differential RXR and RAR activity of stilbene retinoid analogs. Bioorg Med Chem Lett 1994; 4: 1447-52.
34. Benbrook DM. Refining retinoids with heteroatoms. Mini Rev Med Chem 2002; 2: 277-83.
35. Renaud JP, Rochel N, Ruff M, et al. Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid. Nature 1995; 378: 681-9.
36. Gehin M, Vivat V, Wurtz JM, et al. Structural basis for engineering of retinoic acid receptor isotype-selective agonists and antagonists. Chem Biol 1999; 6: 519-29.
37. Lehmann JM, Jong L, Fanjul A, et al. Retinoids selective for retinoid X receptor response pathways. Science 1992; 258: 1944-6.
38. Schulman IG, Crombie D, Bissonette RP, et al. In: Nau H, Blaner WS Eds, Retinoids. The biochemical and molecular basis of vitamin A and retinoid action. Berlin, Springer 1999; 215-35.
39. Brzozowski AM, Pike AC, Dauter Z, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997; 389: 753-8.
40. Shiau AK, Barstad D, Loria PM, et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998; 95: 927-37.
41. Schapira M, Raaka BM, Samuels HH, Abagyan R. Rational discovery of novel nuclear hormone receptor antagonists. Proceedings of the National Academy of Sciences 2000; 97: 1008-13.
42. Cavasotto CN, Liu G, James SY, et al. Determinants of retinoid X receptor transcriptional antagonism. J Med Chem 2004; 47: 4360-72.
43. Gottardis MM, Bischoff ED, Shirley MA, Wagoner MA, Lamph WW, Heyman RA. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res 1996; 56: 5566-70.
44. Bischoff ED, Gottardis MM, Moon TE, Heyman RA, Lamph WW. Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma. Cancer Res 1998; 58: 479-84.
45. Oridate N, Suzuki S, Higuchi M, Mitchell MF, Hong WK, Lotan R. Involvement of reactive oxygen species in N-(4-hydroxyphenyl) retinamide-induced apoptosis in cervical carcinoma cells. J Natl Cancer Inst 1997; 89: 1191-8.
46. Sun SY, Yue P, Lotan R. Induction of apoptosis by N-(4-hydroxyphenyl) retinamide and its association with reactive oxygen species, nuclear retinoic acid receptors, and apoptosis-related genes in human prostate carcinoma cells. Mol Pharmacol 1999; 55: 403-10.
47. Fanjul AN, Delia D, Pierotti MA, Rideout D, Qiu J, Pfahl M. 4-hydroxyphenyl retinamide is a highly selective activator of retinoid receptors. J Biol Chem 1996; 271: 22441-6.
48. Bernard A, Bernardon J-M, Delescluse C, et al. Identification of synthetic retinoids with selectivity for human nuclear retinoic acid receptor γ. Biochem Biophys Res Commun 1992; 186: 977-83.
49. Lu XP, Fanjul A, Picard N, Shroot B, Pfahl M. A selective retinoid with high activity against an androgen-resistant prostate cancer cell type. Int J Cancer 1999; 272-8.
50. Ocker M, Herold C, Ganslmayer M, Hahn EG, Schuppan D. The synthetic retinoid adapalene inhibits proliferation and induces apoptosis in colorectal cancer cells in vitro. Int J Cancer 2003; 107: 453-9.
51. Ocker M, Herold C, Ganslmayer M, Zopf S, Hahn EG, Schuppan D. Potentiated anticancer effects on hepatoma cells by the retinoid adapalene. Cancer Lett 2004; 208: 51-8.
52. Fuentes-Prior P, Salvesen GS. The protein structures that shape caspase activity, specificity, activation and inhibition. Biochem J 2004; 384: 201-32.
53. Kroemer G, Martin SJ. Caspase-independent cell death. Nat Med 2005; 11: 725-30.
54. Danial NK, Korsmeyer SJ. Cell death: critical control points. Cell 2004; 116: 205-19.
55. Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 2003; 10: 26-35.
56. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 1999; 15: 269-90.
57. Ravagnan L, Roumier T, Kroemer G. Mitochondria, the killer organelles and their weapons. J Cell Physiol 2002; 192: 131-7.
58. Nakagawa T, Zhu H, Morishima N, et al. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 2000; 403: 98-103.
59. Zhivotovsky B, Orrenius S. Caspase-2 function in response to DNA damage. Biochem Biophys Res Commun 2005; 331: 859-67.
60. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
61. Korsmeyer SJ. BCL-2 gene family and the regulation of programmed cell death. Cancer Res 1999; 59: 1693s-700s.
62. Vander Heiden MG, Thompson CB. Bcl-2 proteins: regulators of apoptosis or of mitochondrial homeostasis? Nat Cell Biol 1999; 1: E209-E216.
63. Korsmeyer SJ. Chromosomal translocations in lymphoid malignancies reveal novel proto-oncogenes. Annu Rev Immunol 1992; 10: 785-807.
64. Campos L, Rouault JP, Sabido O, et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993; 81: 3091-6.
65. Deveraux QL, Reed JC. IAP family proteins - suppressors of apoptosis. Genes Dev 1999; 13: 239-52.
66. Ekert PG, Silke J, Vaux DL. Caspase inhibitors. Cell Death Differ 1999; 6: 1081-6.
67. Thome M, Tschopp J. Regulation of lymphocyte proliferation and death by FLIP. Nature Rev Immunol 2001; 1: 50-8.
68. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes & Dev 1999; 13: 2905-27.
69. Baeuerle PA, Baltimore D. NF-kappa B: ten years after. Cell 1996; 87: 13-20.
70. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nature Rev Cancer 2002; 2: 301-10.
71. Wang CY, Cusack JCJ, Liu R, Baldwin ASJ. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 1999; 5: 412-7.
72. Lopez-Hernandez FJ, Ortiz MA, Bayon Y, Piedrafita FJ. Retinoid-related molecules require caspase 9 for the effective release of Smac and the rapid induction of apoptosis. Cell Death Differ 2004; 11: 154-64.
73. Zhang Y, Huang Y, Rishi AK, et al. Activation of the p38 and JNK/SAPK mitogen-activated protein kinase pathways during apoptosis is mediated by a novel retinoid. Exp Cell Res 1999; 247: 233-40.
74. Mologni L, Ponzanelli I, Bresciani F, et al. The novel synthetic retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) causes apoptosis in acute promyelocytic leukemia cells through rapid activation of caspases. Blood 1999; 93: 1045-61.
75. Marchetti P, Zamzani N, Joseph B, et al. The novel retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphtalene carboxylic acid can trigger apoptosis through a mitochondrial pathway independent of the nucleus. Cancer Res 1999; 59: 6257-66.
76. Rishi AK, Sun RJ, Gao Y, et al. Post-transcriptional regulation of the DNA damage-inducible gadd45 gene in human breast carcinoma cells exposed to a novel retinoid CD437. Nucleic Acids Res 1999; 27: 3111-9.
77. Sakaue M, Adachi H, Jetten AM. Post-transcriptional regulation of MyD118 and GADD45 in human lung carcinoma cells during 6-[3- (1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid-induced apoptosis. Mol Pharmacol 1999; 55: 668-76.
78. Li Y, Lin B, Agadir A, et al. Molecular determinants of AHPN (CD437)-induced growth arrest and apoptosis in human lung cancer cell lines. Moll Cell Biol 1998; 18: 4719-31.
79. Sun SY, Yue P, Shroot B, Hong WK, Lotan R. Implication of c-Myc in apoptosis induced by the retinoid CD437 in human lung carcinoma cells. Oncogene 1999; 18: 3894-901.
80. Sun SY, Yue P, Wu GS, et al. Implication of p53 in growth arrest and apoptosis induced by the synthetic retinoid CD437 in human lung cancer cells. Cancer Res 1999; 59: 2829-33.
81. Li H, Kolluri SK, Gu J, et al. Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. Science 2000; 289: 1159-64.
82. Hsu CA, Rishi AK, Su-Li X, et al. Retinoid induced apoptosis in leukemia cells through a retinoic acid nuclear receptor-independent pathway. Blood 1997; 89: 4470-9.
83. Sun SY, Yue P, Chandraratna RA, Tesfaigzi Y, Hong WK, Lotan R. Dual mechanisms of action of the retinoid CD437: nuclear retinoic acid receptor-mediated suppression of squamous differentiation and receptor-independent induction of apoptosis in UMSCC22B human head and neck squamous cell carcinoma cells. Mol Pharmacol 2000; 58: 508-14.
84. Bayon Y, Ortiz MA, Lopez-Hernandez FJ, et al. Inhibition of IκB kinase by a new class of retinoid-related anticancer agents that induce apoptosis. Mol Cell Biol 2003; 23: 1061-74.
85. Holmes WF, Dawson MI, Soprano RD, Soprano KJ. Induction of apoptosis in ovarian carcinoma cells by AHPN/CD437 is mediated by retinoic acid receptors. J Cell Physiol 2000; 185: 61-7.
86. Belzacq AS, El Hamel C, Vieira HL, et al. Adenine nucleotide translocator mediates the mitochondrial membrane permeabilization induced by lonidamine, arsenite and CD437. Oncogene 2001 2001; 20: 7579-87.
87. Ortiz MA, Lopez-Hernandez FJ, Bayon Y, Pfahl M, Piedrafita FJ. Retinoid-related Molecules Induce Cytochrome c Release and Apoptosis through Activation of c-Jun NH(2)-Terminal Kinase/p38 Mitogen-activated Protein Kinases. Cancer Res 2001; 61: 8504-12.
88. Lopez-Hernandez FJ, Ortiz MA, Bayon Y, Piedrafita FJ. Z-FA-fink inhibits effector caspases but not initiator caspases 8 and 10, and demonstrates that novel anticancer retinoid-related molecules induce apoptosis via the intrinsic pathway. Mol Cancer Ther 2003; 2: 255-63.
89. Cao X, Liu W, Lin F, et al. Retinoid X receptor regulates Nur77/ TR3-dependent apoptosis by modulating its nuclear export and mitochondrial targeting. Mol Cell Biol 2004; 24: 9705-25.
90. Lin B, Kolluri SK, Lin F, et al. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell 2004; 116: 527-40.
91. Sun SY, Yue P, Hong WK, Lotan R. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-Adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells. Cancer Res 2000; 60: 7149-55.
92. Sun SY, Yue P, Hong WK, Lotan R. Induction of Fas expression and augmentation of Fas/Fas ligand-mediated apoptosis by the synthetic retinoid CD437 in human lung cancer cells. Cancer Res 2000; 60: 6537-43.
93. Chun KH, Pfahl M, Lotan R. Induction of apoptosis by the synthetic retinoid MX3350-1 through extrinsic and intrinsic pathways in head and neck squamous carcinoma cells. Oncogene 2005; 24: 3669-77.
94. Sheikh MS, Augereau P, Chalbos D, Garcia M, Rochefort H. Retinoid regulation of human cathepsin D gene expression. J Steroid Biochem Mol Biol 1996; 57: 283-91.
95. Zang Y, Beard RL, Chandraratna RA, Kang JX. Evidence of a lysosomal pathway for apoptosis induced by the synthetic retinoid CD437 in human leukemia HL-60 cells. Cell Death Differ 2001; 8: 477-85.
96. Adachi H, Adams A, Hughes FM, Zhang J, Cidlowski JA, Jetten AM. Induction of apoptosis by the novel retinoid AHPN in human T-cell lymphoma cells involves caspase-dependent and independent pathways. Cell Death Differ 1998; 5: 973-83.
97. Dawson MI, Harris DL, Liu G, et al. Antagonist analogue of 6-[3′-(1-adamantyl)- 4′-hydroxyphenyl]-2-naphthalenecarboxylic acid (AHPN) family of apoptosis inducers that effectively blocks AHPN-induced apoptosis but not cell-cycle arrest. J Med Chem 2004; 47: 3518-36.
98. Sun SY, Yue P, Wu GS, et al. Implication of p53 in growth arrest and apoptosis induced by the synthetic retinoid CD437 in human lung cancer cells. Cancer Res 1999; 59: 2829-33.
99. Hsu SL, Yin SC, Liu MC, Reichert U, Ho WL. Involvement of cyclin-dependent kinase activities in CD437-induced apoptosis. Exp Cell Res 1999; 252: 332-41.
100. Zhang Y, Rishi AK, Dawson MI, et al. S-phase arrest and apoptosis induced in normal mammary epithelial cells by a novel retinoid. Cancer Res 2000; 60: 2025-32.
101. Boisvieux-Ulrich E, Sourdeval M, Marano F. CD437, a synthetic retinoid, induces apoptosis in human respiratory epithelial cells via caspase-independent mitochondrial and caspase-8-dependent pathways both up-regulated by JNK signaling pathway. Exp Cell Res 2005; 307: 76-90.
102. Wanner R, Henseleit-Walter U, Wittig B, Kolde G. Proliferation-dependent induction of apoptosis by the retinoid CD437 in p53-mutated keratinocytes. J Mol Med 2002; 80: 61-7.
103. Zhao X, Demary K, Wong L, et al. Retinoic acid receptor-independent mechanism of apoptosis of melanoma cells by the retinoid CD437 (AHPN). Cell Death Differ 2001; 8: 878-86.
104. Garattini E, Gianni M, Terao M. Retinoid related molecules an emerging class of apoptotic agents with promising therapeutic potential in oncology: pharmacological activity and mechanisms of action. Curr Pharm Des 2004; 10: 433-48.
105. Liu J, Lin A. Role of JNK activation in apoptosis: a double-edged sword. Cell Res 2005; 15: 36-42.
106. Tournier C, Hess P, Yang DD, et al. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 2000; 288: 870-4.
107. Maundrell K, Antonsson B, Magnenat E, et al. Bcl-2 undergoes phosphorylation by c-Jun N-terminal kinase/stress-activated protein kinases in the presence of the constitutively active GTP-binding protein Rac1. J Biol Chem 1997; 272: 25238-42.
108. Yamamoto K, Ichijo H, Korsmeyer S. Bcl-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G2/M. Moll Cell Biol 1999; 19: 8469-78.
109. Donovan N, Becker EB, Konishi Y, Bonni A. JNK Phosphorylation and Activation of BAD Couples the Stress-activated Signaling Pathway to the Cell Death Machinery. J Biol Chem 2002; 277: 40944-9.
110. Lei K, Davis RJ. JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. Proc Natl Acad Sci U S A 2003; 100: 2432-7.
111. Schadendorf D, Kern MA, Artuc M, et al. Treatment of melanoma cells with the synthetic retinoid CD437 induces apoptosis via activation of AP-1 in vitro, and causes growth inhibition in xenografts in vivo. J Cell Biol 1996; 135: 1889-98.
112. Holmes WF, Soprano DR, Soprano KJ. Early events in the induction of apoptosis in ovarian carcinoma cells by CD437: activation of the p38 MAP kinase signal pathway. Oncogene 2003; 22: 6377-86.
113. Lopez-Hernandez FJ, Ortiz MA, Bayon Y, Piedrafita FJ. Reduced concentrations of serum enhance the antiproliferative activity of retinoid-related molecules and accelerate the onset of apoptosis. Biochem Pharmacol 2003; 65: 2021-30.
114. Pfahl M, Piedrafita FJ. Retinoid targets for apoptosis induction. Oncogene 2003; 22: 9058-62.
115. DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M. A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature 1997; 388: 548-54.
116. Li ZW, Chu W, Hu Y, et al. The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. J Exp Med 1999; 189: 1839-45.
117. Hu Y, Baud V, Oga T, Kim KI, Yoshida K, Karin M. IKKalpha controls formation of the epidermis independently of NF-kappaB. Nature 2001; 410: 710-4.
118. Li Q, Lu Q, Hwang JY, et al. IKK1-deficient mice exhibit abnormal development of skin and skeleton. Genes Dev 1999; 13: 1322-8.
119. Cao Y, Bonizzi G, Seagroves TN, et al. IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell 2001; 107: 763-75.
120. Greten FR, Eckmann L, Greten TF, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118: 285-96.
121. Na SY, Kang BY, Chung SW, et al. Retinoids inhibit interleukin-12 production in macrophages through physical associations of retinoid X receptor and NFkappaB. J Biol Chem 1999; 274: 7674-80.
122. Farhana L, Dawson MI, Fontana JA. Apoptosis induction by a novel retinoid-related molecule requires nuclear factor-kappaB activation. Cancer Res 2005; 65: 4909-17.
123. Jin F, Liu X, Zhou Z, et al. Activation of nuclear factor-kappaB contributes to induction of death receptors and apoptosis by the synthetic retinoid CD437 in DU145 human prostate cancer cells. Cancer Res 2005; 65: 6354-63.
124. Altucci L, Rossin A, Raffelsberger W, Reitmair A, Chomienne C, Gronemeyer H. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat Med 2001; 7: 680-6.
125. Shishodia S, Gutierrez AM, Lotan R, Aggarwal BB. N-(4-hydroxyphenyl)retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of I(kappa)B(alpha) kinase and nuclear factor-kappaB-regulated gene products. Cancer Res 2005; 65: 9555-65.
126. Bayon Y, Ortiz MA, Lopez-Hernandez FJ, Howe PH, Piedrafita FJ. The retinoid antagonist MX781 induces clusterin expression in prostate cancer cells via heat shock factor-1 and activator protein-1 transcription factors. Cancer Res 2004; 64: 5905-12.
127. Yang CR, Leskov K, Hosley-Eberlein K, et al. Nuclear clusterin/XIP8, an x-ray-induced Ku70-binding protein that signals cell death. Proc Natl Acad Sci U S A 2000; 97: 5907-12.
128. Leskov KS, Klokov DY, Li J, Kinsella TJ, Boothman DA. Synthesis and functional analyses of nuclear clusterin, a cell death protein. J Biol Chem 2003; 278: 11590-600.
129. Scaltriti M, Santamaria A, Paciucci R, Bettuzzi S. Intracellular clusterin induces G2-M phase arrest and cell death in PC-3 prostate cancer cells1. Cancer Res 2004; 64: 6174-82.
130. Fleury C, Mignotte B, Vayssiere JL. Mitochondrial reactive oxygen species in cell death signaling. Biochimie 2002; 84: 131-41.
131. Hail N, Jr., Youssef EM, Lotan R. Evidence supporting a role for mitochondrial respiration in apoptosis induction by the synthetic retinoid CD437. Cancer Res 2001; 61: 6698-702.
132. Charpentier B, Bernardon JM, Eustache J, et al. Synthesis, structure-affinity relationships, and biological activities of ligands binding to retinoic acid receptor subtypes. J Med Chem 1995; 38: 4993-5006.
133. Dawson MI, Hobbs PD, Peterson VJ, et al. Apoptosis induction in cancer cells by a novel analogue of 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalenecarboxylic acid lacking retinoid receptor transcriptional activation activity. Cancer Res 2001; 61: 4723-30.
134. Zhang Y, Dawson MI, Mohammad R, et al. Induction of apoptosis of human B-CLL and ALL cells by a novel retinoid and its nonretinoidal analog. Blood 2002; 100: 2917-25.
135. Cincinelli R, Dallavalle S, Merlini L, et al. A novel atypical retinoid endowed with proapoptotic and antitumor activity. J Med Chem 2003; 46: 909-12.
136. Zanchi C, Zuco V, Lanzi C, Supino R, Zunino F. Modulation of survival signaling pathways and persistence of the genotoxic stress as a basis for the synergistic interaction between the atypical retinoid ST1926 and the epidermal growth factor receptor inhibitor ZD1839. Cancer Res 2005; 65: 2364-72.
137. Garattini E, Parrella E, Diomede L, et al. ST1926, a novel and orally active retinoid-related molecule inducing apoptosis in myeloid leukemia cells: modulation of intracellular calcium homeostasis. Blood 2004; 103: 194-207.
138. Keedwell RG, Zhao Y, Hammond LA, et al. A retinoid-related molecule that does not bind to classical retinoid receptors potently induces apoptosis in human prostate cancer cells through rapid caspase activation. Cancer Res 2004; 64: 3302-12.
139. Reitmair A, Shurland DL, Tsang KY, Chandraratna RA, Brown G. Retinoid-related molecule AGN193198 potently induces G2M arrest and apoptosis in bladder cancer cells. Int J Cancer 2005; 115: 917-23.
140. Balasubramanian S, Chandraratna RA, Eckert RL. A novel retinoid-related molecule inhibits pancreatic cancer cell proliferation by a retinoid receptor independent mechanism via suppression of cell cycle regulatory protein function and induction of caspase-associated apoptosis. Oncogene 2005; 24: 4257-70.
141. Ponzanelli I, Gianni M, Giavazzi R, et al. Isolation and characterization of an acute promyelocytic leukemia cell line selectively resistant to the novel antileukemic and apoptogenic retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalene carboxylic acid. Blood 2000; 95: 2672-82.
142. Holmes WF, Soprano DR, Soprano KJ. Elucidation of Molecular Events Mediating Induction of Apoptosis by Synthetic Retinoids Using a CD437-resistant Ovarian Carcinoma Cell Line. J Biol Chem 2002; 277: 45408-19.
143. Fontana JA, Dawson MI, Leid M, et al. Identification of a unique binding protein specific for a novel retinoid inducing cellular apoptosis. Int J Cancer 2000; 86: 474-9.
144. Benbrook DM, Madler MM, Spruce LW, et al. Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity. J Med Chem 1997; 40: 3567-83.
145. Zacheis D, Dhar A, Lu S, et al. Heteroarotinoids inhibit head and neck cancer cell lines in vitro and in vivo through both RAR and RXR retinoic acid receptors. J Med Chem 1999; 42: 4434-45.